97311 ⎘
Antibody mimetics or scaffolds Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Bispecific EGFR/C-Met Antibodies
#2DARPIN-CONTAINING COMPOSITIONS AND METHODS THEREOF
#3CD40L-SPECIFIC TN3-DERIVED SCAFFOLDS FOR THE TREATMENT AND PREVENTION OF SJÖGREN'S SYNDROME
#4BINDING MEMBERS WITH ALTERED DIVERSITY SCAFFOLD DOMAINS
#5T CELL RECEPTORS RECOGNIZING HLA-A1-RESTRICTED MAGE-A3
#6DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF
#7WNT SIGNALING AGONIST MOLECULES
#8LIPOPOLYSACCHARIDE-BINDING PEPTOIDS, AND COMPOSITIONS AND METHODS OF USE THEREOF
#9SCAFFOLD PROTEINS
#10COMPOSITIONS COMPRISING A TN3 SCAFFOLD AND METHODS OF USING THE SAME
#11Set of Photoreceptor Protein and Affibody
#12ANTI-B7-H3 COMPOUNDS AND METHODS OF USE
#13SARS-COV-2 NEUTRALIZING SYNTHETIC PROTEINS
#14IL-17A-BINDING POLYPEPTIDES
#15BINDING PROTEINS SPECIFIC FOR CD32A
#16NOVEL DARPIN BASED CD70 ENGAGERS
#17IL-IR-I BINDING POLYPEPTIDE
#18DESIGNED REPEAT DOMAINS WITH DUAL BINDING SPECIFICITY AND THEIR USE
#19WNT SIGNALING AGONIST MOLECULES
#20Antiviral Agent Comprising a Cellular Entry Receptor and Fc Region Component
#21PROTEIN-BASED CONJUGATION CARRIERS
#22STABILIZED TCR CONSTRUCTS AND METHODS OF USE
#23CD40L-SPECIFIC TN3-DERIVED SCAFFOLDS FOR THE TREATMENT AND PREVENTION OF SJÖGREN'S SYNDROME
#24CD40L-SPECIFIC TN3-DERIVED SCAFFOLDS FOR USE IN THE TREATMENT AND PREVENTION OF RHEUMATOID ARTHRITIS
#25NOVEL DARPIN BASED CD33 ENGAGERS
#26Scaffold proteins
#27MCL-1 BINDING ALPHABODIES AND USES THEREOF
#28EPITOPE-SCAFFOLD IMMUNOGENS FOR PANCORONAVIRUS VACCINES
#29ANTIGEN BINDING POLYPEPTIDES
#30FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9
#31Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof
#32MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS
#33ONCOLYTIC VIROTHERAPY WITH INDUCED ANTI-TUMOR IMMUNITY
#34NEW HER2-BINDING POLYPEPTIDE
#35TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS
#36Serum Albumin-Binding Fibronectin Type III Domains
#37Heteromultivalent Nucleic Acid Scaffolds and Uses Thereof
#38RECOMBINANT CD3 BINDING PROTEINS AND THEIR USE
#39DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF
#40N-Terminal Capping Modules of Ankyrin Repeat Domains
#41NPC1 MONOBODIES AND MONOBODY CONJUGATES THEREOF
#42TESTOSTERONE-SPECIFIC AFFIBODY AND USES THEREOF
#43ANTIBODY-LIKE PROTEIN AND USE THEREOF
#44MULTIMERIC PROTEIN COMPLEXES AS ANTIBODY SUBSTITUTES FOR NEUTRALIZATION OF VIRAL PATHOGENS IN PROPHYLACTIC AND THERAPEUTIC APPLICATIONS
#45LENTIVIRAL VECTORS ENABLING ROUTING ANTIGENS TO MHC-II PATHWAY AND INDUCING CD4+ AND CD8+ T-CELL RESPONSES IN A HOST
#46ENGINEERED BINDING PROTEINS FOR RECOGNITION OF BACTERIA
#47DESIGNED ANKYRIN REPEAT DOMAINS WITH ALTERED SURFACE RESIDUES
#48SERUM STABLE BINDING PROTEINS FOR HUMAN HER2 FOR THERANOSTIC APPLICATIONS
#49Antibody Derivatives with Conditionally Enabled Effector Function
#50DPP3 BINDER DIRECTED TO AND BINDING TO SPECIFIC DPP3-EPITOPES AND ITS USE IN THE PREVENTION OR TREATMENT OF DISEASES/ACUTE CONDITIONS THAT ARE ASSOCIATED WITH OXIDATIVE STRESS
#51STABILIZED FIBRONECTIN BASED SCAFFOLD MOLECULES
#52CELL SURFACE CONJUGATES AND RELATED CELL COMPOSITIONS AND METHODS
#53Multifunctional Heteromultimeric Constructs
#54VARIANTS OF SAC7D AND THEIR USE IN CANCER THERAPY
#55Multivalent D-Peptidic Compounds for Target Proteins
#56INSERTABLE VARIABLE FRAGMENTS OF ANTIBODIES AND MODIFIED A1-A2 DOMAINS OF NKG2D LIGANDS
#57CHIMERIC RECEPTOR SENSORS
#58Anti-thyroglobulin t cell receptors
#59Peptide for the delivery of anionic materials
#60TRIFUNCTIONAL T CELL-ANTIGEN COUPLER AND METHODS AND USES THEREOF
#61COMPOSITIONS AND METHODS FOR TREATING CANCER
#62RECOMBINANT 4-1BB BINDING PROTEINS AND THEIR USE
#63ENGINEERED T CELLS AND USES THEREFOR
#64SINGLE CHAIN FUSIONCONSTRUCTS COMPRISING MULTIMERIC ANTIBODY FRAGMENTS FUSED TO COLLAGEN TRIMERIZATION DOMAINS
#65RECOMBINANT FAP BINDING PROTEINS AND THEIR USE
#66ANTI-ADRENOMEDULLIN (ADM) BINDER FOR USE IN THERAPY OR PREVENTION OF SYMPTOMS OF ILLNESS
#67T CELL RECEPTORS RECOGNIZING HLA-A1-RESTRICTED MAGE-A3
#68BINDING MOLECULES BINDING PD-L1 AND LAG-3
#69LAG-3 binding members
#70Lipocalin muteins with binding affinity for LAG-3
#71CHIMERIC PROTEINS
#72Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomer
#73Designed ankyrin repeat domains with altered surface residues
#74WNT SIGNALING AGONIST MOLECULES
#75IL-IR-I binding polypeptide
#76Bispecific EGFR/c-Met antibodies
#77VEGF Antagonist Formulations
#78BINDERS FOR INHIBITING FORMATION OF MULTIMERIC PROTEINS
#79Affibody proteins specific for B7-H3 (CD276)
#80Cysteine engineered fibronectin type III domain binding molecules
#81Fibronectin based scaffold domain proteins that bind PCSK9
#82Methods of treatment of IL-17A associated conditions
#83VEGF Antagonist Formulations
#84DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF
#85Serum albumin-binding fibronectin type III domains
#86DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
#87EGFR and C-met fibronectin type III domain binding molecules
#88MULTISPECIFIC ANTIBODY PRODUCT THAT BINDS TO DIFFERENT ROR1 EPITOPES
#89Switch molecule and switchable chimeric antigen receptor
#90Trifunctional T cell-antigen coupler and methods and uses thereof
#91POLYPEPTIDE IMPROVED IN PROTEIN PURITY AND AFFINITY FOR ANTIGEN, CONJUGATE THEREOF WITH ANTIBODY OR ANTIGEN-BINDING FRAGMENT, AND PREPARATION METHOD THEREFOR
#92Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS
#93Optimized variants of anti-VEGF antibodies
#94TRISPECIFIC INHIBITORS FOR CANCER TREATMENT
#95CARTYRIN COMPOSITIONS AND METHODS FOR USE
#96Citrate buffered VEGF antagonist formulations
#97TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR
#98PD-L1 binding fibronectin type III domains
#99DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF
#100DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF
#101Chemical probe-dependent evaluation of protein activity and uses thereof
#102Fibronectin binding domains with reduced immunogenicity
#103Tumor-selective CTLA-4 antagonists
#104Cell surface conjugates and related cell compositions and methods
#105CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS
#106Compositions and methods for treating cancer
#107Trifunctional T cell-antigen coupler and methods and uses thereof
#108Fibronectin based scaffold proteins
#109De novo binding domain containing polypeptides and uses thereof
#110Multi-chain polypeptide-containing tri-specific binding molecules
#111Tri-specific binding molecules that specifically bind to multiple cancer antigens
#112OB-fold used as scaffold for engineering new specific binders
#113Scaffold proteins
#114Engineered antibodies for the detection of phosphorylated tyrosine
#115BIOMIMETIC POLYMERS FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES
#116Fibronectin binding domains with reduced immunogenicity
#117Anti-thyroglobulin T cell receptors
#118Glycosaminoglycan Mimetic Scaffolds
#119Bispecific EGFR/C-Met Antibodies
#120Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
#121Trifunctional T cell-antigen coupler and methods and uses thereof
#122Stabilized fibronectin based scaffold molecules
#123PSMA-specific binding proteins
#124Disintegrin variants and pharmaceutical uses thereof
#125Formulations of VEG antagonist fusion proteins and method of manufacturing them
#126Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
#127Multifunctional heteromultimeric constructs
#128CHIMERIC RECEPTORS, BIOSENSOR HOST CELLS AND METHODS/USES THEREOF
#129Chimeric proteins
#130Lipocalin muteins with binding affinity for LAG-3
#131LAG-3 binding members
#132CHIMERIC ANTIGEN RECEPTORS (CARS) SPECIFIC FOR MUC1 AND METHODS FOR THEIR USE
#133Chimeric proteins
#134NOVEL BINDING PROTEINS COMPRISING A UBIQUITIN MUTEIN AND ANTIBODIES OR ANTIBODY FRAGMENTS
#135Peptide-DNA chimeras for treatment of HER overexpressing cancers
#136Cysteine engineered fibronectin type III domain binding molecules
#137Fibronectin based scaffold proteins having improved stability
#138Recombinant binding proteins and their use
#139Glucocorticoid receptor agonist and immunoconjugates thereof
#140BINDING MEMBERS WITH ALTERED DIVERSITY SCAFFOLD DOMAINS
#141Binding molecules binding PD-L1 and LAG-3
#142Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS
#143EGFR binding molecules
#144Polypeptide exhibiting affinity to antibodies forming non-native three-dimensional structure
#145Bispecific EGFR/IGFIR binding molecules
#146Glycosylated repeat-motif-molecule conjugates
#147Optimized variants of anti-vegf antibodies and methods of use thereof in treatment
#148Fc γ RIII binding fibronectin type III domains, their conjugates and multispecific molecules comprising them
#149Method for generating high affinity, bivalent binding agents for sandwich assays
#150Polynucleotides encoding optimized variants of anti-VEGF antibodies
#151T cell receptors recognizing HLA-A1- or HLA-CW7-restricted mage
#152Anti-cancer fusion polypeptide
#153Blood-brain barrier permeable peptide compositions comprising a VAB domain of an anti-amyloid-beta camelid single-domain heavy-chain only antibody
#154ANTIBODY AND ANTIBODY MIMETIC FOR VISUALIZATION AND ABLATION OF ENDOGENOUS PROTEINS
#155Single chain fusionconstructs comprising multimeric antibody fragments fused to collagen trimerization domains
#156Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2)
#157PSMA-specific binding proteins
#158Nucleic acids encoding a Tn3 scaffold comprising a CD40L-specific monomer subunit
#159Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins
#160Bispecific EGFR/C-Met Antibodies
#161De novo binding domain containing polypeptides and uses thereof
#162De novo binding domain containing polypeptides and uses thereof
#163Anti-thyroglobulin T cell receptors
#164Targeted therapeutics based on engineered proteins that bind EGFR
#165POLYPEPTIDES
#166Miniature protein scaffolds and methods for use thereof
#167Antibody derivatives with conditionally enabled effector function
#168Tumor-selective CTLA-4 antagonists
#169DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF
#170Methods and composition for modifying enzymes
#171Fibronectin based scaffold domain proteins that bind PCSK9
#172PD-L1 binding fibronectin type III domains
#173Libraries of modified fibronectin type III tenth domain-containing polypeptides
#174FIBRONECTIN-BASED BINDING MOLECULES AND USES THEREOF
#175Bispecific T cell activating antigen binding molecules
#176Polynucleotides encoding bispecific EGFR/IGF-IR binding molecules
#177NOVEL BINDING PROTEINS COMPRISING A UBIQUITIN MUTEIN AND ANTIBODIES OR ANTIBODY FRAGMENTS
#178Engineered T cells and uses therefor
#179Methods for allergy diagnosis
#180HUMAN NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (HNGAL) MUTEINS THAT BIND HEPCIDIN AND NUCLEIC ACID ENCODING SUCH
#181Method of treating cancer with a multiple integrin binding Fc fusion protein
#182IL-17A-binding polypeptides
#183Method of manufacturing VEGF antagonist fusion proteins
#184Serum albumin-binding fibronectin type III domains
#185Fusion polypeptide capable of binding simultaneously to VEGF-C and VEGF-D
#186Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
#187Generating Targeted Sequence Diversity in Proteins
#188PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS AND OTHER BINDING PROTEINS
#189RNA-PROTEIN COMPLEX, AND RNA AND PROTEIN DELIVERY SYSTEM USING THE SAME
#190Capping modules for designed ankyrin repeat proteins
#191WNT signaling agonist molecules
#192EGFR and c-Met fibronectin type III domain binding molecules
#193FUSION PROTEINS COMPRISING IMMUNOGLOBULIN CONSTANT DOMAIN-DERIVED SCAFFOLDS
#194Bispecific EGFR/C-Met Antibodies
#195Trispecific inhibitors for cancer treatment
#196PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS AND OTHER BINDING PROTEINS
#197BIOMIMETIC POLYMERS FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES
#198UNIVERSAL FIBRONECTIN TYPE III BINDING-DOMAIN LIBRARIES
#199Soluble engineered monomeric Fc
#200Affinity proteins and uses thereof
#201Chimeric antigen receptor compositions
#202INTRACELLULAR ANTIGEN BINDING
#203Polypeptide for binding to complement protein C5A, and use of same
#204Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigens
#205Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
#206Polypeptides targeting vascular endothelial growth factor receptor and prostate specific membrane antigen
#207Multi-chain polypeptide-containing tri-specific binding molecules
#208Stabilized fibronectin based scaffold molecules
#209OB-fold used as scaffold for engineering new specific binders
#210Fibronectin based scaffold proteins having improved stability
#211Fibronectin binding domains with reduced immunogenicity
#212IL-6-binding polypeptide complex
#213Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis
#214Polypeptide binding to extracellular domain of epidermal growth factor receptor
#215Antibody-fynomer conjugates
#216Engineered antibody constant domain molecules
#217VEGF ANTAGONIST FORMULATIONS
#218Fibronectin binding domains with reduced immunogenicity
#219Compositions and methods for treating cancer
#220Fc fusion proteins comprising novel linkers or arrangements
#221Trifunctional T cell-antigen coupler and methods and uses thereof
#222Multi-specific polypeptide useful for localized tumor immunomodulation
#223Recombinant binding proteins and their use
#224Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
#225Alphabody libraries and methods for producing the same
#226Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands
#227Inhibitors of type 2 vascular endothelial growth factor receptors
#228Polypeptides
#229ANTICALINS
#230Designed ankyrin repeat proteins binding to hepatocyte growth factor
#231Designed repeat proteins binding to serum albumin
#232Stabilized fibronectin domain compositions, methods and uses
#233VEGF specific fusion protein antagonist formulations
#234High affinity synbodies for influenza
#235Stable VEGF antagonist formulations
#236Fibronectin based scaffold domain proteins that bind PCSK9
#237Insertable variable fragments of antibodies and modified A1-A2 domains of NKG2D ligands
#238Synbodies for detection of human norovirus
#239Targeted therapeutics based on engineered proteins that bind EGFR
#240Capping modules for designed ankyrin repeat proteins
#241SINGLE-CHAIN ANTIPARALLEL COILED COIL PROTEINS
#242Reconstituted polypeptides
#243OB-fold used as scaffold for engineering new specific binders
#244Fusion protein comprising targeting moiety, cleavage site, and cell membrane penetrating domain, and use thereof
#245Fusion proteins comprising immunoglobulin constant domain-derived scaffolds
#246Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
#247Generating targeted sequence diversity in proteins
#248Fusion protein comprising granzyme B and use thereof
#249IL-17A binding molecules and medical uses thereof
#250Binding proteins comprising at least two repeat domains against HER2
#251Recognition tags for TGase-mediated conjugation
#252Fibronectin based scaffold domain proteins that bind IL-23
#253Polypeptides capable of cellular internalization
#254Polypeptides specifically binding to IL-23
#255Method of treating cancer by administering EGFR and EGFR/IGFIR binding molecules
#256α/β-peptide mimics of Z-domain peptides
#257METHOD FOR IMPROVING REPEBODY CONTAINING REPEAT MODULES
#258Cysteine engineered fibronectin type III domain binding molecules
#259CD40L-specific TN3-derived scaffolds and methods of use thereof
#260Fibronectin binding domains with reduced immunogenicity
#261Binding molecules with antitumoral activity
#262Bispecific chimeric proteins comprising DARPins
#263Fusion polypeptide inhibiting VEGF-C, VEGF-D and/or angiopoietin-2, and use thereof
#264BINDING AGENTS TO INTRACELLULAR TARGET MOLECULES
#265Multivalent fibronectin based scaffold domain proteins
#266Antibody and antibody mimetic for visualization and ablation of endogenous proteins
#267Bispecific EGFR/c-Met antibodies
#268Inhibitors of type 2 vascular endothelial growth factor receptors
#269EGFR and C-Met fibronectin type III domain binding molecules
#270EGFR and c-Met fibronectin type III domain binding molecules
#271Protein scaffolds
#272Bispecific EGFR/c-Met antibodies
#273Universal fibronectin type III binding-domain libraries
#274Fc fusion proteins comprising novel linkers or arrangements
#275Alphabody libraries and methods for producing the same
#276Fibronectin cradle molecules and libraries thereof
#277Compositions and methods for treating cancer
#278Targeted therapeutics based on engineered proteins that bind EGFR
#279Engineered antibody constant domain molecules
#280Designed ankyrin repeat proteins binding to platelet-derived growth factor
#281Fibronectin based scaffold domain proteins that bind IL-23
#282Fibronectin binding domains with reduced immunogenicity
#283Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins that bind hepcidin and nucleic acid encoding such
#284Designed repeat proteins binding to serum albumin
#285Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
#286Reconstituted polypeptides
#287Fibronectin based scaffold domain proteins that bind PCSK9
#288Fibronectin binding domains with reduced immunogenicity
#289Fibronectin based scaffold proteins having improved stability
#290Bispecific EGFR/IGFIR binding molecules
#291Nucleic acids molecule encoding the polypeptide for treating virus-induced cancer
#292RNF8-FHA domain-modified protein and method of producing the same
#293Method of producing the polypeptide for treating virus-induced cancer
#294TRAIL R2-specific multimeric scaffolds
#295Fibronectin based scaffold domain proteins that bind IL-23
#296Multivalent fibronectin based scaffold domain proteins
#297GLYCOSYLATED REPEAT-MOTIF-MOLECULE CONJUGATES
#298Antibody Mimetic Scaffolds
#299Methods of inhibiting type 2 vascular endothelial growth factor receptors using polypeptides
#300MULTISPECIFIC MODULAR ANTIBODY